Thu, Dec 26, 2024
[Archive]
Volume 14, Issue 1 ( March 2022 2022)
Iranian Journal of Blood and Cancer 2022, 14(1): 6-11 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Montazeri-Najafabady N, Dabbaghmanesh M H, Chatrabnous N, Arabnezhad M R, Mohammadian Amiri R. Mir 143 rs353293 G>A Polymorphism is Not Associated with the Risk of Thyroid Cancer in the Iranian Population: A Case-Control Study. Iranian Journal of Blood and Cancer 2022; 14 (1) :6-11
URL: http://ijbc.ir/article-1-1022-en.html
URL: http://ijbc.ir/article-1-1022-en.html
Nima Montazeri-Najafabady1 
, Mohammad Hossein Dabbaghmanesh * 2, Nazanin Chatrabnous1 , Mohammad Reza Arabnezhad1 , Rajeeh Mohammadian Amiri1
, Mohammad Hossein Dabbaghmanesh * 2, Nazanin Chatrabnous1 , Mohammad Reza Arabnezhad1 , Rajeeh Mohammadian Amiri1
1- Shiraz Endocrine and Metabolism Research Center, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
2- Shiraz Endocrine and Metabolism Research Center, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran ,dabbaghm@sums.ac.ir
2- Shiraz Endocrine and Metabolism Research Center, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran ,
Abstract: (1739 Views)
Background: Single nucleotide polymorphisms (SNPs) in the promoter region of miRNAs may disturb miRNAs processing, alter their expression, and ultimately affect an individual’s susceptibility to cancer. We conducted a case-control study to evaluate the association of rs353293 G>A with the risk of thyroid cancer in the Iranian population.
Methods: 192 patients with thyroid cancer including (papillary, follicular, medullary, and undifferentiated) and 125 healthy subjects were enrolled in this case-control study. rs353293 G>A polymorphism in the promoter region of miR-143/145 were analyzed using polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP) to find the association of this SNP with thyroid cancer. Logistic regression analyses were conducted to evaluate adjusted odds ratios (ORs) for the potential confounding factors (age and sex), and 95% confidence intervals (95% CIs) between patients with thyroid cancer and controls.
Results: We found no association between rs353293 G>A polymorphism and thyroid cancer.
Conclusion: This study suggests that the functional polymorphism in rs353293 is not associated with development of thyroid cancer. Future investigations with larger sample size should be performed to confirm our observations.
: Original Article |
Subject:
Genetics
Received: 2020/06/16 | Accepted: 2022/03/8 | Published: 2022/04/30
Received: 2020/06/16 | Accepted: 2022/03/8 | Published: 2022/04/30
References
1. Saenko VA, Rogounovitch TI. Genetic Polymorphism Predisposing to Differentiated Thyroid Cancer: A Review of Major Findings of the GenomeWide Association Studies. Endocrinol Metab. 2018;33(2):164-74. [DOI:10.3803/EnM.2018.33.2.164]
2. Dong G, Zhang R, Xu J, Guo Y. Association between microRNA polymorphisms and papillary thyroid cancer susceptibility. Int J Clin Exp Pathol.. 2015;8(10):13450-7.
3. Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence andmortality in the united states, 1974-2013. JAMA. 2017;317(13):1338-48. [DOI:10.1001/jama.2017.2719]
4. Chen P, Sun R, Pu Y, Bai P, Yuan F, Liang Y, et al. Pri-Mir-34b/C and Tp-53 Polymorphisms are Associated With The Susceptibility of Papillary Thyroid Carcinoma: A Case-Control Study. Medicine. 2015;94(38):e1536. [DOI:10.1097/MD.0000000000001536]
5. He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A.2005;102(52):19075-80. [DOI:10.1073/pnas.0509603102]
6. Jazdzewski K, Murray EL, Franssila K, Jarzab B, Schoenberg DR, de la Chapelle A. Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci U S A. 2008;105(20):7269-74. [DOI:10.1073/pnas.0802682105]
7. Kotlarek M, Kubiak A, Czetwertynska M, Swierniak M, Gierlikowski W, Kolanowska M, et al. The rs2910164 Genetic Variant of miR-146a-3p Is Associated with Increased Overall Mortality in Patients with Follicular Variant Papillary Thyroid Carcinoma. Int J Mol Sci.2018;19(3). [DOI:10.3390/ijms19030655]
8. Zhao Y, Li X, Zhu S. rs78378222 polymorphism in the 3'-untranslated region of TP53 contributes to development of age-associated cataracts by modifying microRNA-125b-induced apoptosis of lens epithelial cells. Mol Med Rep. 2016;14(3):2305-10. [DOI:10.3892/mmr.2016.5465]
9. McVeigh TP, Mulligan RJ, McVeigh UM, Owens PW, Miller N, Bell M, et al. Investigating the association of rs2910164 with cancer predisposition in an Irish cohort. Endocr Connect. 2017;6(8):614-24. [DOI:10.1530/EC-17-0196]
10. Hu Z, Chen J, Tian T, Zhou X, Gu H, Xu L, et al. Genetic variants of miRNA sequences and nonsmall cell lung cancer survival. J Clin Invest. 2008;118(7):2600-8. [DOI:10.1172/JCI34934]
11. Zang Z, Guan W, Chen D, Han Y, Shi Z, Zhou J. Association Between microRNA-125a rs12976445 C>T Polymorphism and 18F-Fluorodeoxyglucose (18FDG) Uptake: Clinical and Metabolic Response in Patients with Non-Small Cell Lung Cancer. Med Sci Monit.2016;22:4186-92. [DOI:10.12659/MSM.897255]
12. Wu J, Huang Q, Meng D, Huang M, Li C, Qin T. A Functional rs353293 Polymorphism in the Promoter of miR-143/145 Is Associated with a Reduced Risk of Bladder Cancer. PloS one. 2016;11(7):e0159115. [DOI:10.1371/journal.pone.0159115]
13. de la Chapelle A, Jazdzewski K. MicroRNAs in thyroid cancer. J Clin Endocrinol Metab. 2011;96(11):3326-36. [DOI:10.1210/jc.2011-1004]
14. Li L, Pan X, Li Z, Bai P, Jin H, Wang T, et al. Association between polymorphisms in the promoter region of miR-143/145 and risk of colorectal cancer. Hum Immunol. 2013;74(8):993-7. [DOI:10.1016/j.humimm.2013.04.019]
15. Chu H, Zhong D, Tang J, Li J, Xue Y, Tong N, et al. A functional variant in miR-143 promoter contributes to prostate cancer risk. Arch Toxicol. 2016;90(2):403- 14. [DOI:10.1007/s00204-014-1396-2]
16. Liang Y, Sun R, Li L, Yuan F, Liang W, Wang L, et al. A Functional Polymorphism in the Promoter of MiR-143/145 Is Associated With the Risk of Cervical Squamous Cell Carcinoma in Chinese Women: A Case-Control Study. Medicine. 2015;94(31):e1289. [DOI:10.1097/MD.0000000000001289]
17. Wei WJ, Wang YL, Li DS, Wang Y, Wang XF, Zhu YX, et al. Association between the rs2910164 polymorphism in pre-Mir-146a sequence and thyroid carcinogenesis. PloS one. 2013;8(2):e56638. [DOI:10.1371/journal.pone.0056638]
18. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res.. 1988;16(3):1215. doi: 10.1093/nar/16.3.1215. [DOI:10.1093/nar/16.3.1215]
19. Liu Y, Zhang Y, Wen J, Liu L, Zhai X, Liu J, et al. A genetic variant in the promoter region of miR-106b-25 cluster and risk of HBV infection and hepatocellular carcinoma. PLoS One. 2012; 7(2). E32230. [DOI:10.1371/journal.pone.0085394]
20. Jahanbani I, Al-Abdallah A, Ali RH, Al-Brahim N, Mojiminiyi O. Discriminatory miRNAs for the Management of Papillary Thyroid Carcinoma and Noninvasive Follicular Thyroid Neoplasms with Papillary-Like Nuclear Features. Thyroid. 2018;28(3):319-27. [DOI:10.1089/thy.2017.0127]
21. Zhang C. MicroRNomics: a newly emerging approach for disease biology. Physiol Genomics. 2008;33(2):139-47. [DOI:10.1152/physiolgenomics.00034.2008]
22. Yang T, Zhai H, Yan R, Zhou Z, Gao L, Wang L. lncRNA CCAT1 promotes cell proliferation, migration, and invasion by down-regulation of miR-143 in FTC-133 thyroid carcinoma cell line. Braz J Med Biol Res. 2018;51(6):e7046. [DOI:10.1590/1414-431x20187046]
23. Liu L, Yu X, Guo X, Tian Z, Su M, Long Y, et al. miR-143 is downregulated in cervical cancer and promotes apoptosis and inhibits tumor formation by targeting Bcl-2. Mol Med Rep. 2012;5(3):753-60. [DOI:10.3892/mmr.2011.696]
24. Su J, Liang H, Yao W, Wang N, Zhang S, Yan X, et al. MiR-143 and MiR-145 regulate IGF1R to suppress cell proliferation in colorectal cancer. PloS One. 2014;9(12):e114420. [DOI:10.1371/journal.pone.0114420]
25. Yan X, Chen X, Liang H, Deng T, Chen W, Zhang S, et al. miR-143 and miR-145 synergistically regulate ERBB3 to suppress cell proliferation and invasion in breast cancer. Mol Cancer. 2014;13:220. [DOI:10.1186/1476-4598-13-220]
26. Clape C, Fritz V, Henriquet C, Apparailly F, Fernandez PL, Iborra F, et al. miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice. PloS One. 2009;4(10):e7542. [DOI:10.1371/journal.pone.0007542]
27. Villadsen SB, Bramsen JB, Ostenfeld MS, Wiklund ED, Fristrup N, Gao S, et al. The miR-143/-145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer. Br J Cancer. 2012;106(2):366-74. [DOI:10.1038/bjc.2011.520]
28. Wu D, Huang P, Wang L, Zhou Y, Pan H, Qu P. MicroRNA-143 inhibits cell migration and invasion by targeting matrix metalloproteinase 13 in prostate cancer. Mol Med Rep. 2013;8(2):626-30. [DOI:10.3892/mmr.2013.1501]
29. Chen X, Guo X, Zhang H, Xiang Y, Chen J, Yin Y, et al. Role of miR-143 targeting KRAS in colorectaltumorigenesis. Oncogene. 2009;28(10):1385-92. [DOI:10.1038/onc.2008.474]
30. Akao Y, Nakagawa Y, Naoe T. MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers. Oncol Rep. 2006;16(4):845-50. [DOI:10.3892/or.16.4.845]
31. Tang J., Research on the association between polymorphism in the promoter region of microRNA-143 and susceptibility to protate cancer [D]. Nanjing: Nanjing Medical University; 2011.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
- Iranian Journal of Blood and Cancer
- Journal Tel: +989369936116
- Publisher Tel: +982122275917
- Mail: Info@ijbc.ir
